PTMs, especially tumor-relevant PTMs, may therefore provide novel therapeutic avenues for cancer.
In exploring novel PTM of the RAS-MAPK signaling cascade, Mazur et al. [4] examined the potential role of lysine methylation signaling in oncogenic RAS-driven tumors by conducting an expression survey of 54 human lysine methyltransferases (KMTs) in pancreatic ductal adenocarcinoma (PDAC), a cancer type where KRAS is mutated in about 90% of cases. Five KMTs were found to be overexpressed in human PDAC, including SMYD3, MLL5, EZH2, SETD5 and WHSC1L1. Previous work demonstrated that EZH2 overexpression is linked to the disease aggressiveness and WHSC1L1 resides in an amplicon in human PDAC [5, 6] . Muzur et al. focused on SMYD3 given that it acts in the cytosol where KRAS also functions and SMYD3 shows the most significant correlation with PDAC progression. To substantiate a role for SMYD3 in Kras-mediated tumorigenesis, Smyd3 was conditionally deleted in the classical Kras G12D -driven PDAC and lung cancer mouse models. In both models, Smyd3 deficiency suppresses the development of Kras G12D -induced tumor formation and significantly prolongs overall survival, supporting a role for Smyd3 in Ras-driven cancer development and progression. Importantly, reconstitution with wild-type Smyd3, but not a catalytic inactive mutant, restores the tumorigenic activity in Smyd3-deficient animals, providing crucial evidence that the enzymatic activity of Smyd3 is required for its oncogenic function.
To identify SMYD3 targets, 9 000 potential substrates were screened on a protein array platform and, strikingly, the only robust methylation target of SMYD3 was MAP3K2. In summary, this very elegant study opens new vistas for tackling oncogenic KRAS-driven cancers though some outstanding issues remain to be addressed. SMYD3 was shown to be overexpressed in RAS-driven tumors. However, it is not clear whether its expression is regulated by Ras signaling. On the other hand, recent study indicated that the output of oncogenic Ras signaling needs to be amplified to induce tumor development in pancreatic cancer [7] . It is possible that the activation of MAPK through SMYD3-mediated MAP3K2 methylation serves to bring oncogenic Ras signaling above pathological threshold to ensure malignant progression. Second, the study focused on the role of SMYD3-mediated methylation on MAP3K2 in oncogenic Ras-driven tumors. However, the data indicated that such modification should also be functional in tumor cells with wild-type Ras. To expand the translational potential of SMYD3 targeting, further studies are needed to characterize the function of SMYD3-mediated methylation in tumors driven by other oncogenes between traditional kinase inhibitors, such as MEK or PI3K inhibitors, and other PTM inhibitors in cancers driven by oncogenic RAS, the emperor of all oncogenes. such as EGFR and HER2 where Ras may function as an essential mediator in tumor development. Finally, while the development of second-generation small-molecule inhibitors of epigenetic proteins is rapidly emerging for cancer therapies, this study indicates the importance of auditing the activities of these compounds not only on their traditional chromatin targets but also on cellular proteins with integral roles in cancer. While the RAS oncogene itself is under heavy post-translational modification [8] , it is now clear that other components of the RAS pathway are also regulated by PTMs other than phosphorylation. In addition to the study by Mazur et al., it has been previously shown that MEK2 and MEK6 are acetylated at key serine residues which block their phosphorylation and the subsequent activation of MAPK pathway [9, 10] . However, how these PTMs are regulated by driver oncogenes and the biochemical and functional relationships between these modifications are less understood. Comprehensive studies are needed to catalog the global changes across these PTMs that are induced by oncogene activation or upon targeted therapy. Such characterization should illuminate the rational development of new combination strategies
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